This Is Not a Generic Tanning-Peptide Course

"Melanotan I" is the kind of name that makes peptide education harder than it needs to be. In modern medical use, the meaningful identity is afamelanotide, marketed as SCENESSE, with a specific evidence-backed role in erythropoietic protoporphyria (EPP).

This course starts by clearing up the naming confusion, then rebuilds the topic from the real pillars: MC1R biology, eumelanin signaling, EPP light toxicity, clinical trials, safety monitoring, regulation, and the distinction from Melanotan II.

what this course covers

01 From Melanotan I to Afamelanotide free 02 MC1R Biology & Melanocortin Signaling 03 Chemistry, Sequence Design & PK 04 EPP Pathophysiology & Light Toxicity 05 Pivotal Trials in EPP 06 Real-World Evidence & Long-Term Use 07 Safety, Pigmentation & Monitoring 08 Implant Dosing & Clinical Use 09 Regulatory Status & Orphan-Drug Context 10 Vitiligo & Adjacent Indications 11 MT-I vs MT-II vs PT-141 12 Final Exam & Certification

From Alpha-MSH to Afamelanotide

The molecule makes more sense when you start with the endogenous hormone lineage.

Afamelanotide comes out of the alpha-melanocyte-stimulating hormone lineage, which is why the course centers receptor biology instead of internet folklore. Older naming conventions such as "Melanotan I" still show up online, but the clinical evidence lives under the afamelanotide / SCENESSE identity.

That naming split matters. One framing leads to a discussion about approved photoprotection in EPP; the other often drifts into gray-market tanning talk. This course keeps those paths separate.

naming confusion: "Melanotan I" is a research-era label. the approved drug is afamelanotide (brand name SCENESSE). this course uses the clinical identity throughout, but references the older name where historically accurate.

The Alpha-MSH Lineage

MC1R signaling and eumelanin matter more here than the buzzword "tanning."

alpha-MSH lineage: afamelanotide is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), a 13-amino-acid endogenous peptide. the key modification -- Nle4, D-Phe7 substitution -- dramatically increases metabolic stability and MC1R binding affinity over the native hormone.

interactive mc1r map

Why EPP Is the Real Clinical Story

The strongest evidence is about pain-free light exposure, not casual cosmetic use.

In EPP, visible-light exposure can trigger severe phototoxic pain. That changes the meaning of "more light tolerance" from a cosmetic concept into a functional clinical outcome. Afamelanotide is taught here through that lens.

Once you understand EPP, the pivotal trial endpoints stop looking vague. They become direct measures of day-to-day function in a disease where daylight itself can be disabling.

Why This Is Not a Tanning Course

The gray market collapsed multiple melanocortin stories into one. That is exactly what this course fixes.

important context: afamelanotide should not be taught as a sunscreen replacement, a cosmetic free-for-all, or a synonym for Melanotan II. Those shortcuts break the evidence base.

What You Will Learn

The rest of the course moves from receptor biology into disease context, trials, monitoring, regulation, and family-tree distinctions.

course structure: units 2-3 cover MC1R biology and chemistry. units 4-6 cover EPP pathophysiology and clinical evidence. units 7-9 cover safety, dosing, and regulation. units 10-11 cover adjacent indications and melanocortin-family distinctions. unit 12 is the final exam.

MC1R

core receptor target

EPP

core clinical use case

12

units including final exam

Evidence-first

not gray-market folklore

FDA 2019

approved for EPP in adults

1 in 75k

estimated EPP prevalence

60 days

implant therapeutic window

Eumelanin

photoprotective pigment target

Knowledge Check

Confirm the naming, receptor, and disease-context fundamentals before moving deeper.

Practice

Reinforce the distinctions that matter most for the rest of the course.